Need Help?

560 whole-genome sequenced breast cancers

A comprehensive characterisation and analysis of 560 human breast cancers through genome-wide approaches including genomics, transcriptomics and epigenomics.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00010000915 Affymetrix SNP6.0 344
EGAD00010000916 Illumina 450k 457
EGAD00010000917 Agilent miRNA microarrays 399
EGAD00010001911 H and E image 151
Publications Citations
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nature 534: 2016 47-54
1175
Co-transcriptional R-loops are the main cause of estrogen-induced DNA damage.
Elife 5: 2016 e17548
154
The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
PLoS One 11: 2016 e0161731
9
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.
Nat Commun 7: 2016 12910
65
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers.
Nat Genet 49: 2017 341-348
55
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Nat Med 23: 2017 517-525
487
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.
Nature 543: 2017 714-718
142
Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
PLoS Comput Biol 14: 2018 e1006192
13
Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers.
Cancers (Basel) 10: 2018 E500
5
The Identification and Interpretation of cis-Regulatory Noncoding Mutations in Cancer.
High Throughput 8: 2018 E1
4
The circular RNome of primary breast cancer.
Genome Res 29: 2019 356-366
63
Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.
Breast Cancer Res 21: 2019 25
15
A practical guide for mutational signature analysis in hematological malignancies.
Nat Commun 10: 2019 2969
105
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Nat Genet 51: 2019 1450-1458
165
A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies.
Nat Cancer 1: 2020 249-263
115
DNA copy number motifs are strong and independent predictors of survival in breast cancer.
Commun Biol 3: 2020 153
9
Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor.
Nat Commun 11: 2020 4875
18
Revealing the impact of structural variants in multiple myeloma.
Blood Cancer Discov 1: 2020 258-273
54
The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.
Clin Cancer Res 27: 2021 5430-5439
12
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.
Nat Commun 12: 2021 5668
57
Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data.
Gigascience 10: 2021 giab080
7
Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression.
JCO Precis Oncol 6: 2022 e2100190
4
Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer.
Cancers (Basel) 14: 2022 753
1
Substitution mutational signatures in whole-genome-sequenced cancers in the UK population.
Science 376: 2022 science.abl9283
73
Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Breast Cancer Res 25: 2023 53
3
Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.
Nature 621: 2023 129-137
2
Most large structural variants in cancer genomes can be detected without long reads.
Nat Genet 55: 2023 2139-2148
5
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
Breast Cancer Res 25: 2023 145
0
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.
Cell Rep Med 4: 2023 101344
0